SBIR/STTR Research Award

Fenofibrate Eye Drop for the Treatment of Diabetic Retinopathy

Award identifier 6a7456e39a241b42fd4f778212a9376329abad35d75941f898f8a4930fcf6c23Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$185,550

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Charlesson, LLC
Proposal award date
2016-09-01
Contract end date
2018-08-31
UEI
EBG6FJ52JJX3
Solicitation number
PA14-071
Topic code
N

Research abstract

DESCRIPTION provided by applicant This Small Business Innovation Research project aims to develop an innovative eye drop formulation for the treatment of diabetic retinopathy The goal of this proposal is to develop substantial efficacy safety and pharmacokinetic data to support the clinical development of topical fenofibrate We hypothesize that topical application of fenofibrate can reduce vision loss and neovascularization in animal models of diabetes and retinal disease The goal of this proposal is to evaluate the efficacy of topical fenofibrate on preventing visual acuity loss in a rat model of streptozotocin induced diabetes We will give fenofibrate eye drops either two or four times a day for weeks We will measure the change of visual acuity over this time period The long term goal Phase is to perform safety studies and find a commercial manufacturer for the formulation PUBLIC HEALTH RELEVANCE Nearly all patients with type diabetes and andgt of type diabetic patients will develop some form of retinopathy and visual loss in their lifetime Fenofibrate is a peroxisome proliferator activated receptor alpha PPAR agonist that has been shown in both The Fenofibrate Intervention and Event Lowering in Diabetes FIELD and The Action to Control Cardiovascular Risk in Diabetes ACCORD clinical trials to reduce the progression of diabetic retinopathy in diabetic patients Oral fenofibrate appears to have limited systemic benefit in diabetic patients thus the topical application of fenofibrate for diabetic eye disease represents a more targeted and safe approach to treat diabetic retinopathy

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

23 SBIR/STTR records share this UEI (2004–2016). Reported award amounts total $10,337,136. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.